最近 Strauss 等报道急性粒细胞自血病定期预防性输注粒细胞没有裨益,不必常规输注。但多数作者认为预防和治疗性粒细胞输注至少对畋血症患者有用。因此对有高度败血症危险、年老、处于诱导治疗伴有发热、欲进入第二次缓解和长期极度中性粒细胞减少的急性白血病患者,输注粒细胞可能有益。Strauss 等指出,粒细胞输注副反应多,但若注意组织配型,供者服皮质激素,受者于输注前服皮质激素能减少副反应,并能减少肺部浸润及其他严重肺部病变。谨慎选择供者还能减少巨细胞病毒传播及其他血源性感染。若能提高安全性,并仅予败血症高度危险患者输注,对判断用作预防是否有益的研究才合理。近2年粒细胞输注已少用。其原因是白血病有效 Recently, Strauss et al reported that prophylactic infusion of granulocytes in acute myeloid leukemia was not beneficial and did not require routine infusion. However, most authors believe that prophylaxis and treatment of neutrophil infusions are at least useful in patients with sepsis. Therefore, transfusion of granulocytes may be beneficial in patients with acute leukemia who are at high risk for sepsis, who are old, are in induced therapy with fever, and are expected to enter the second remission and long-term extreme neutropenia. Strauss et al. Showed that there are many side effects of granulocyte transfusion, but if we pay attention to tissue matching and donor corticosteroids, the recipient may reduce side effects by pre-infusion corticosteroids and reduce lung infiltration and other severe lung Lesions. Careful selection of donors can also reduce cytomegalovirus transmission and other blood-borne infections. Studies that justify the use of prophylaxis are only sensible if they improve safety and give infusions only to patients at high risk of sepsis. Nearly 2 years of granulocyte infusion has been less used. The reason is that leukemia is effective